Nevertheless, the linearized multistage procedure used by EPA (U.S. 

 EPA 1986a; also see below, Dose-Response Assessment) yields results 

 that correspond approximately (within a factor of two) to those 

 produced by the linear model used by FDA. The interagency Subcom- 

 mittee on Fish Residue Issues of the EPA Risk Assessment Council, 

 which included representatives from FDA, concluded that the dif- 

 ferences in procedures for modeling dose-response relationships be- 

 tween EPA and FDA were small relative to the uncertainties in other 

 steps of a risk assessment. Therefore, the EPA/FDA policy statement 

 (Appendix A herein) does not discuss procedures to reconcile these 

 differences. 



A final distinction between EPA's risk assessment procedures and 

 other potential approaches is that EPA does not yet provide a stand- 

 ardized approach for assessing carcinogenic effects on children and 

 fetuses. Information on perinatal carcinogenicity is presently being 

 developed by EPA and others. 



